Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of early detection on cancer curability: A modified Delphi panel study.
Schwartzberg L, Broder MS, Ailawadhi S, Beltran H, Blakely LJ, Budd GT, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk BJ, Wong DJ, Campos C, Yermilov I. Schwartzberg L, et al. Among authors: wong dj. PLoS One. 2022 Dec 21;17(12):e0279227. doi: 10.1371/journal.pone.0279227. eCollection 2022. PLoS One. 2022. PMID: 36542647 Free PMC article.
Patient-reported quality of life and adherence outcomes after integrating exclusive liquid meal replacement in patients with head and neck cancer undergoing chemoradiation: results from a phase II study.
Valle LF, Chu FI, Wang X, Erman A, Hernandez J, Kaoh E, Edgar N, Raldow AC, Wong DJ, Steinberg ML, Kishan AU, Chin RK, Hegde JV. Valle LF, et al. Among authors: wong dj. Front Oncol. 2025 Jan 7;14:1433503. doi: 10.3389/fonc.2024.1433503. eCollection 2024. Front Oncol. 2025. PMID: 39839777 Free PMC article.
Therapeutic Advances in Advanced Basal Cell Carcinoma.
Alkassis S, Shatta M, Wong DJ. Alkassis S, et al. Among authors: wong dj. Cancers (Basel). 2024 Sep 4;16(17):3075. doi: 10.3390/cancers16173075. Cancers (Basel). 2024. PMID: 39272933 Free PMC article. Review.
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. Hughes BGM, et al. Among authors: wong dj. J Am Acad Dermatol. 2025 Jan;92(1):68-77. doi: 10.1016/j.jaad.2024.06.108. Epub 2024 Sep 7. J Am Acad Dermatol. 2025. PMID: 39245360 Clinical Trial.
194 results